GSK expects shingles drug sales to exceed $1.3 billion after ‘fantastic’ quarter

GlaxoSmithKline forecast 2019 sales of its fast-growing shingles vaccine Shingrix to be “significantly” more than 1 billion pounds ($1.31 billion) on Wednesday as the British drugmaker outpaced first quarter forecasts.

…read more

Source:: Reuters – Business News